Search:

Home Index Back issues Contact

This item requires a subscription.

Effect of inhaled corticosteroids on bone
RDIP, Volume 18, Number 4.

Current guidelines for the management of asthma advocate early intervention with inhaled corticosteroids.1 These agents are also widely used in the management of chronic obstructive pulmonary disease (COPD). Three compounds are licensed in the UK; beclometasone dipropionate (BDP), budesonide (BUD) and fluticasone propionate (FP).

To view this item, select one of the options below:

Purchase access

In order to view articles you will need to pay a subscription for 24-hour access. You can view all articles on this site during the subscription period.
Please click here to subscribe.
 

Sign in

If you are already have a subscription, please sign in here.

email address

Password

Forgotten your password?

Important

All the articles are in PDF format.

To view the articles you will need Adobe Acrobat Reader.

To download a copy, free of charge,
please click here.

 
Help
  If you need help accessing this site, please click here.

 


The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title Respiratory Disease in Practice is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk